Susan C Short

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9299572/publications.pdf

Version: 2024-02-01

101543 79698 6,038 103 36 73 citations h-index g-index papers 110 110 110 7564 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Prevalence of <i>BRAF</i> V600 in glioma and use of <i>BRAF</i> Inhibitors in patients with <i>BRAF</i> V600 mutation-positive glioma: systematic review. Neuro-Oncology, 2022, 24, 528-540.	1.2	26
2	Long-term impact of adult WHO grade II or III gliomas on health-related quality of life: A systematic review. Neuro-Oncology Practice, 2022, 9, 3-17.	1.6	5
3	Drug Resistance in Glioma Cells Induced by a Mesenchymal–Amoeboid Migratory Switch. Biomedicines, 2022, 10, 9.	3.2	10
4	Increased replication stress and R-loop accumulation in EGFRvIII-expressing glioblastoma present new therapeutic opportunities. Neuro-Oncology Advances, 2022, 4, vdab180.	0.7	2
5	HOX and PBX gene dysregulation as a therapeutic target in glioblastoma multiforme. BMC Cancer, 2022, 22, 400.	2.6	7
6	Intensity standardization of MRI prior to radiomic feature extraction for artificial intelligence research in glioma—a systematic review. European Radiology, 2022, 32, 7014-7025.	4.5	10
7	Glioma progression is shaped by genetic evolution and microenvironment interactions. Cell, 2022, 185, 2184-2199.e16.	28.9	163
8	EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nature Reviews Clinical Oncology, 2021, 18, 170-186.	27.6	826
9	Establishing a Link Between Commonly Reported Toxicities and Tumour Location in Brain Tumour Patients Treated With Volumetric-modulated Arc Radiotherapy. Clinical Oncology, 2021, 33, e97-e98.	1.4	1
10	A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with temozolomide in patients with recurrent glioblastoma. British Journal of Cancer, 2021, 124, 1379-1387.	6.4	66
11	Glycolysis and Fatty Acid Oxidation Inhibition Improves Survival in Glioblastoma. Frontiers in Oncology, 2021, 11, 633210.	2.8	30
12	Hematopoietic stem cell gene therapy targeting $TGF\hat{l}^2$ enhances the efficacy of irradiation therapy in a preclinical glioblastoma model., 2021, 9, e001143.		7
13	GSK-3 Inhibition Is Cytotoxic in Glioma Stem Cells through Centrosome Destabilization and Enhances the Effect of Radiotherapy in Orthotopic Models. Cancers, 2021, 13, 5939.	3.7	5
14	Patient Involvement in the Design of a Randomised Trial of Proton Beam Radiotherapy Versus Standard Radiotherapy for Good Prognosis Glioma. Clinical Oncology, 2020, 32, 89-92.	1.4	5
15	Expression profiling of single cells and patient cohorts identifies multiple immunosuppressive pathways and an altered NK cell phenotype in glioblastoma. Clinical and Experimental Immunology, 2020, 200, 33-44.	2.6	51
16	Profiling cytotoxic microRNAs in pediatric and adult glioblastoma cells by high-content screening, identification, and validation of miR-1300. Oncogene, 2020, 39, 5292-5306.	5.9	5
17	Healthcare utilization and productivity loss in glioma patients and family caregivers: the impact of treatable psychological symptoms. Journal of Neuro-Oncology, 2020, 147, 485-494.	2.9	16
18	Hydroxychloroquine and short-course radiotherapy in elderly patients with newly diagnosed high-grade glioma: a randomized phase II trial. Neuro-Oncology Advances, 2020, 2, vdaa046.	0.7	7

#	Article	IF	CITATIONS
19	EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma. Oncogene, 2020, 39, 3041-3055.	5.9	42
20	Gender issues from the perspective of health-care professionals in Neuro-oncology: an EANO and EORTC Brain Tumor Group survey. Neuro-Oncology Practice, 2020, 7, 249-259.	1.6	1
21	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro-Oncology, 2020, 22, 1073-1113.	1.2	543
22	A novel workflow for three-dimensional analysis of tumour cell migration. Interface Focus, 2020, 10, 20190070.	3.0	4
23	CTIM-14. PELAREOREP AND GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) WITH STANDARD CHEMORADIOTHERAPY/ADJUVANT TEMOZOLOMIDE FOR GLIOBLASTOMA MULTIFORME (GBM) PATIENTS: REOGLIO PHASE I TRIAL RESULTS. Neuro-Oncology, 2020, 22, ii35-ii36.	1.2	1
24	Patient engagement in the design of a randomised trial of proton beam radiotherapy versus photon radiotherapy for good prognosis glioma. Neuro-Oncology, 2019, 21, iv10-iv11.	1.2	0
25	The impact of the neuro-oncology research radiographer role in the effective facilitation of an advanced imaging study in glioblastoma. Neuro-Oncology, 2019, 21, iv17-iv17.	1.2	0
26	Chromatin remodelling to facilitate treatment resistance in glioblastoma. Neuro-Oncology, 2019, 21, iv7-iv7.	1.2	1
27	Chemically-induced neurite-like outgrowth reveals multicellular network function in patient-derived glioblastoma cells. Journal of Cell Science, 2019, 132, .	2.0	6
28	Highlights of the inaugural ten – the launch of Neuro-Oncology Advances. Neuro-Oncology Advances, 2019, 1, vdz016.	0.7	0
29	Hypothalamicâ€pituitary axis irradiation dose thresholds for the development of hypopituitarism in adultâ€onset gliomas. Clinical Endocrinology, 2019, 91, 131-140.	2.4	19
30	FGFR1 Expression and Role in Migration in Low and High Grade Pediatric Gliomas. Frontiers in Oncology, 2019, 9, 103.	2.8	12
31	Senolytics and senostatics as adjuvant tumour therapy. EBioMedicine, 2019, 41, 683-692.	6.1	136
32	Longitudinal molecular trajectories of diffuse glioma in adults. Nature, 2019, 576, 112-120.	27.8	320
33	shRNAâ€mediated PPARα knockdown in human glioma stem cells reduces ⟨i⟩in vitro⟨/i⟩ proliferation and inhibits orthotopic xenograft tumour growth. Journal of Pathology, 2019, 247, 422-434.	4.5	13
34	PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status. Clinical and Translational Radiation Oncology, 2018, 8, 12-16.	1.7	51
35	Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade. Science Translational Medicine, 2018, 10, .	12.4	288
36	Development of clinical simultaneous SPECT/MRI. British Journal of Radiology, 2018, 91, 20160690.	2.2	51

3

#	Article	IF	CITATIONS
37	Selective BCL-XL inhibition promotes apoptosis in combination with MLN8237 in medulloblastoma and pediatric glioblastoma cells. Neuro-Oncology, 2018, 20, 203-214.	1.2	22
38	Systematic Review of Synthetic Computed Tomography Generation Methodologies for Use in Magnetic Resonance Imaging–Only Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 100, 199-217.	0.8	235
39	How to analyse the spatiotemporal tumour samples needed to investigate cancer evolution: A case study using paired primary and recurrent glioblastoma. International Journal of Cancer, 2018, 142, 1620-1626.	5.1	8
40	Evaluating the repeatability and set-up sensitivity of a large field of view distortion phantom and software for magnetic resonance-only radiotherapy. Physics and Imaging in Radiation Oncology, 2018, 6, 31-38.	2.9	22
41	KHS101 disrupts energy metabolism in human glioblastoma cells and reduces tumor growth in mice. Science Translational Medicine, 2018, 10, .	12.4	54
42	RAD51 Is a Selective DNA Repair Target to Radiosensitize Glioma Stem Cells. Stem Cell Reports, 2017, 8, 125-139.	4.8	100
43	Drug-Repositioning Screens Identify Triamterene as a Selective Drug for the Treatment of DNA Mismatch Repair Deficient Cells. Clinical Cancer Research, 2017, 23, 2880-2890.	7.0	19
44	Oncolytic Herpes Simplex Virus Inhibits Pediatric Brain Tumor Migration and Invasion. Molecular Therapy - Oncolytics, 2017, 5, 75-86.	4.4	22
45	Pituitary dysfunction following cranial radiotherapy for adultâ€onset nonpituitary brain tumours. Clinical Endocrinology, 2016, 84, 372-379.	2.4	61
46	Brain Tumours. Medical Radiology, 2016, , 127-142.	0.1	0
47	Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) \hat{a} effectively protocol of a randomized phase II trial (NOA 10/ARO 2013-1). BMC Cancer, 2016, 16, 769.	2.6	62
48	Science in Focus: MicroRNA in Glioma – Potential as Biomarkers and Therapeutic Targets. Clinical Oncology, 2016, 28, 543-546.	1.4	4
49	A validated microRNA profile with predictive potential in glioblastoma patients treated with bevacizumab. Molecular Oncology, 2016, 10, 1296-1304.	4.6	19
50	ESTRO-ACROP guideline "target delineation of glioblastomas― Radiotherapy and Oncology, 2016, 118, 35-42.	0.6	286
51	Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling. Neuro-Oncology, 2016, 18, 518-527.	1.2	57
52	Loss of expression of the tumour suppressor gene <i>AIMP3</i> predicts survival following radiotherapy in muscleâ€invasive bladder cancer. International Journal of Cancer, 2015, 136, 709-720.	5.1	24
53	High-content analysis of tumour cell invasion in three-dimensional spheroid assays. Oncoscience, 2015, 2, 596-606.	2.2	27
54	Towards the production of radiotherapy treatment shells on 3D printers using data derived from DICOM CT and MRI: preclinical feasibility studies. Journal of Radiotherapy in Practice, 2015, 14, 92-98.	0.5	26

#	Article	IF	CITATIONS
55	Diagnostic delay and survival in high-grade gliomas – evidence of the â€~waiting time paradox'?. British Journal of Neurosurgery, 2015, 29, 520-523.	0.8	15
56	Prediction of clinical outcome in glioblastoma using a biologically relevant nineâ€microRNA signature. Molecular Oncology, 2015, 9, 704-714.	4.6	56
57	Position statement on ethics, equipoise and research on charged particle radiation therapy. Journal of Medical Ethics, 2014, 40, 572-575.	1.8	20
58	Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/carcinoma: variable clinical response in preliminary evaluation. Pituitary, 2014, 17, 530-538.	2.9	56
59	Methylation-specific multiplex ligation-dependent probe amplification identifies promoter methylation events associated with survival in glioblastoma. Journal of Neuro-Oncology, 2014, 117, 243-251.	2.9	12
60	Changes in mast cell number and stem cell factor expression in human skin after radiotherapy for breast cancer. Radiotherapy and Oncology, 2014, 111, 206-211.	0.6	7
61	Benchmarking of a treatment planning system for spot scanning proton therapy: Comparison and analysis of robustness to setup errors of photon IMRT and proton SFUD treatment plans of base of skull meningioma. Medical Physics, 2014, 41, 111710.	3.0	9
62	Biological dosimetry for breast cancer radiotherapy: a comparison of external beam and intraoperative radiotherapy. SpringerPlus, 2014, 3, 329.	1.2	8
63	Cytokine levels as biomarkers of radiation fibrosis in patients treated with breast radiotherapy. Radiation Oncology, 2014, 9, 103.	2.7	11
64	Prognostic microRNAs in high-grade glioma reveal a link to oligodendrocyte precursor differentiation. Oncoscience, 2014, 2, 252-262.	2.2	12
65	Multi-disciplinary management for patients with oligometastases to the brain: results of a 5 year cohort study. Radiation Oncology, 2013, 8, 156.	2.7	26
66	Meningioma Causing Visual Impairment: Outcomes and Toxicity After Intensity Modulated Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 85, e179-e186.	0.8	22
67	Sequential Transformation of Mesenchymal Stem Cells is Associated with Increased Radiosensitivity and Reduced DNA Repair Capacity. Radiation Research, 2013, 179, 698-706.	1.5	13
68	The Role of Autophagy in Clinical Practice. Clinical Oncology, 2012, 24, 387-395.	1.4	35
69	Rad51 inhibition is an effective means of targeting DNA repair in glioma models and CD133+ tumor-derived cells. Neuro-Oncology, 2011, 13, 487-499.	1.2	79
70	<i>BRCA1</i> and <i>BRCA2</i> heterozygosity in embryonic stem cells reduces radiation-induced Rad51 focus formation but is not associated with radiosensitivity. International Journal of Radiation Biology, 2010, 86, 1095-1105.	1.8	7
71	Radiosurgery for brain tumours. BMJ: British Medical Journal, 2010, 340, c3247-c3247.	2.3	5
72	Cytotoxic Effects of Temozolomide and Radiation are Additive- and Schedule-Dependent. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1511-1519.	0.8	57

#	Article	IF	Citations
73	Management of Glioblastoma Multiforme in HIV Patients: a Case Series and Review of Published Studies. Clinical Oncology, 2009, 21, 591-597.	1.4	28
74	Re-irradiation of brain tumours â€" evidence, indications and limitations. European Journal of Cancer, 2009, 45, 410-411.	2.8	1
75	Using Retinoids to Increase Radioiodine Uptake in Thyroid Cancer. , 2009, , 991-999.		0
76	Sub-acute blindness in a patient with a temporal lobe astrocytoma. BMJ Case Reports, 2009, 2009, bcr0120091513-bcr0120091513.	0.5	0
77	Survival from brain tumours in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S102-S103.	6.4	3
78	DNA repair after irradiation in glioma cells and normal human astrocytes. Neuro-Oncology, 2007, 9, 404-411.	1.2	49
79	Dose- and Time-Dependent Changes in Gene Expression in Human Glioma Cells after Low Radiation Doses. Radiation Research, 2007, 168, 199-208.	1.5	13
80	ATR-dependent radiation-induced \hat{I}^3 H2AX foci in bystander primary human astrocytes and glioma cells. Oncogene, 2007, 26, 993-1002.	5.9	179
81	Late Toxicity Is Not Increased in <i>BRCA1/BRCA2</i> Mutation Carriers Undergoing Breast Radiotherapy in the United Kingdom. Clinical Cancer Research, 2006, 12, 7025-7032.	7.0	75
82	Acute Chemotherapy–Related Toxicity Is Not Increased in BRCA1 and BRCA2 Mutation Carriers Treated for Breast Cancer in the United Kingdom. Clinical Cancer Research, 2006, 12, 7033-7038.	7.0	36
83	Diffuse pigmented villonodular synovitis of the foot and ankle treated with surgery and radiotherapy. International Orthopaedics, 2005, 29, 403-405.	1.9	39
84	Low-dose hyperradiosensitivity of human glioblastoma cell linesin vitrodoes not translate into improved outcome of ultrafractionated radiotherapyin vivo. International Journal of Radiation Biology, 2005, 81, 751-758.	1.8	35
85	DNA Damage Responses at Low Radiation Doses. Radiation Research, 2005, 164, 292-302.	1.5	62
86	Low dose hyper-radiosensitivity in metastatic tumors. International Journal of Radiation Oncology Biology Physics, 2004, 59, 1190-1195.	0.8	63
87	Primary Central Nervous System Lymphoma with Testicular Relapse. Clinical Oncology, 2004, 16, 193-195.	1.4	7
88	A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer. Clinical Oncology, 2004, 16, 569-574.	1.4	61
89	The evaluation of low dose hyper-radiosensitivity in normal human skin. Radiotherapy and Oncology, 2004, 70, 319-329.	0.6	38
90	Effects of cell cycle phase on low-dose hyper-radiosensitivity. International Journal of Radiation Biology, 2003, 79, 99-105.	1.8	90

#	Article	IF	Citations
91	Ultrafractionation in A7 human malignant glioma in nude mice. International Journal of Radiation Biology, 2003, 79, 377-383.	1.8	29
92	Low-Dose Reduction in Transformation Frequency Compared to Unirradiated Controls: The Role of Hyper-radiosensitivity to Cell Death. Radiation Research, 2003, 159, 433-436.	1.5	64
93	Radiobiology and vascular targeting in glioma. Current Opinion in Neurology, 2003, 16, 651-655.	3.6	2
94	Effects of cell cycle phase on low-dose hyper-radiosensitivity. International Journal of Radiation Biology, 2003, 79, 99-105.	1.8	29
95	Effects of cell cycle phase on low-dose hyper-radiosensitivity. International Journal of Radiation Biology, 2003, 79, 99-105.	1.8	19
96	Temozolomide as second-line chemotherapy for relapsed gliomas. Journal of Neuro-Oncology, 2002, 57, 247-251.	2.9	26
97	Low-dose hypersensitivity after fractionated low-dose irradiation in vitro. International Journal of Radiation Biology, 2001, 77, 655-664.	1.8	110
98	Low-dose hypersensitivity: current status and possible mechanisms. International Journal of Radiation Oncology Biology Physics, 2001, 49, 379-389.	0.8	508
99	Thalidomide as an anti-angiogenic agent in relapsed gliomas. Journal of Neuro-Oncology, 2001, 51, 41-45.	2.9	7 5
100	The response of human glioma cell lines to low-dose radiation exposure. International Journal of Radiation Biology, 1999, 75, 1341-1348.	1.8	73
101	Cellular response to low-dose irradiation. Clinical Oncology, 1998, 10, 73-77.	1.4	18
102	Neuro-Oncology. , 0, , 771-822.		1
103	NOTCH blockade combined with radiation therapy and temozolomide prolongs survival of orthotopic glioblastoma. Oncotarget, 0, 7, 41251-41264.	1.8	65